Myriad Genetics, Inc., a leading molecular diagnostic company,  announced that Janssen Research & Development, LLC, will use Myriad's BRACAnalysis test in connection with its phase III clinical trial of Yondelis (trabectedin) in the treatment of advanced-relapsed epithelial ovarian, primary peritoneal or fallopian tube cancers (NCT01846611). Specific terms of the deal were not disclosed.

"We are delighted to be collaborating with Janssen and applying our more than 20 years of BRCA-testing experience to help advance clinical cancer research," said Mark C Capone, president of Myriad Genetics Laboratories. "A key element of our business strategy is to partner with major pharmaceutical companies to establish BRACAnalysis as the leading companion diagnostic and this partnership is yet another important step toward that goal and the era of precision medicine and personalized healthcare."

Myriad's BRACAnalysis is the gold standard diagnostic test to confirm the presence of a BRCA1 or BRCA2 gene mutations. BRACAnalysis has been used by approximately 60,000 healthcare providers to test more than one million patients.

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.